For most patients diagnosed with a pulmonary embolism, anticoagulation is the primary and often sufficient treatment. But for a subset of cases, the clinical team must weigh whether anticoagulation alone is enough or whether a more active intervention — such as catheter-directed thrombolysis or mechanical thrombectomy — is warranted. This is not a decision made lightly, and it depends on several converging factors rather than any single test result.
Why Anticoagulation Is the Default Starting Point
Anticoagulants do not dissolve an existing clot directly; instead, they prevent new clot from forming and allow the body's own fibrinolytic system to gradually break down the existing thrombus over time. For a low-risk PE — typically a smaller clot burden without evidence of right heart strain or hemodynamic compromise — this approach is generally effective and carries a well-established safety profile. The vast majority of PE cases fall into this category and are managed successfully with anticoagulation alone, without the need for further intervention.
When Does the Conversation Shift Toward Intervention?
The decision to consider intervention generally hinges on risk stratification. Patients with evidence of right heart strain — seen on echocardiography, elevated cardiac biomarkers, or CT findings of right ventricular enlargement — are classified as intermediate-risk, and those with hemodynamic instability or shock are classified as high-risk or massive PE. It is primarily within these categories that catheter-based options enter the discussion, since anticoagulation alone works more slowly than mechanical or pharmacomechanical clot removal, and a patient who is hemodynamically unstable may not have the physiologic reserve to wait for that gradual resolution.
Weighing Clot Burden and Location
The size and location of the clot burden matters considerably. A large, centrally located clot obstructing major pulmonary arteries is more likely to prompt consideration of active clot removal than a smaller, more peripheral embolism, because central clots carry a greater potential to cause acute right heart failure. Imaging findings, together with the patient's hemodynamic trend over the hours following diagnosis, help the team judge whether the clot burden justifies the additional risks associated with an invasive procedure.
The Risk-Benefit Calculation Is Not One-Sided
Intervention carries its own risks, including bleeding, vessel injury, and procedural complications, which must be weighed against the potential benefit of more rapid clot reduction. This is why intervention is not simply offered to every intermediate-risk patient — many are managed successfully with anticoagulation and close monitoring, with escalation reserved for those who show signs of clinical deterioration. A multidisciplinary pulmonary embolism response team often supports this decision-making process specifically because it requires balancing competing risks across specialties.
Device Options When Intervention Is Chosen
When the care team determines that intervention is appropriate, options may include catheter-directed thrombolysis, large-bore aspiration thrombectomy, or, in patients where anticoagulation is contraindicated, an IVC filter to reduce further embolic risk. These devices and their indicated use are described in detail in each product's Instructions for Use (IFU); an overview of the device categories available for this pathway is provided on INVAMED's pulmonary embolism management page. The decision to use any specific device rests with the treating physician based on the individual patient's presentation.
Is intervention ever chosen even when a patient is hemodynamically stable?
Yes, in select cases. Some intermediate-risk patients with substantial right heart strain or large clot burden may be considered for catheter-directed therapy even while hemodynamically stable, particularly if there are signs suggesting a risk of deterioration. This determination is made by the treating team weighing the specific risk-benefit profile of that patient.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.